Uncommonly Funded Cancer Research Gains Momentum with Accolades
Curebound, a philanthropic organization that funds groundbreaking cancer research, announces significant updates for its grant recipients. The 2021 recipient...
Jon Napitupulu
Bristol Myers Squibb Achieves FDA Acceptance for Treatment Option in Hepatocellular Carcinoma
Bristol Myers Squibb has announced the acceptance by the U.S. Food and Drug Administration (FDA) of its application for...
QuantHealth’s Remarkable AI Powers $215 Million Savings for Pharma Giants
QuantHealth, a pioneering AI-powered clinical trial design company, has reached a milestone with over 100 successful simulated trials. This...
Immune Checkpoint Receptor Knock-down in Glioblastoma Model: Promising Advance for Cancer Immunotherapy
EMulate Therapeutics’ manuscript, “Magnetic Field Emulations of Small Inhibitor RNA: Effects on GL261 Tumors,” has been accepted for publication...
IGC Pharma: AI Advances Therapeutic Potential for Metabolic and Neurological Diseases
The discovery of IGC-1A’s potential as a GLP-1 agonist, resulting from IGC Pharma’s advanced Artificial Intelligence (AI) modeling, has...
Walgreens, BARDA Team Up to Empower Decentralized Clinical Trials
Walgreens and the Biomedical Advanced Research and Development Authority (BARDA) have joined forces to enhance decentralized clinical trials through...
Bristol Myers Squibb’s Revolutionary CAR T Cell Therapy for Lymphoma Gains EMA Validation
The European Medicines Agency (EMA) has validated an application to expand the indication of Breyanzi for treating relapsed or...
Bitt Immune Technologies and Therapeutics Announces Exclusive NIH Funding for Clinical Trial with Otsuka
Boston Immune Technologies and Therapeutics (BITT), a developer of TNFSR antagonist antibodies, has partnered with McQuade Center for Strategic...
Pfizer and BioNTech Announce Results From New Combo Vaccine for Influenza and COVID-19
Pfizer and BioNTech have released preliminary findings from a Phase 3 clinical trial evaluating their mRNA vaccine candidate that...
Incyte Reveals Promise in Cancer Treatment with Revolutionary Drug
A pivotal Phase 3 trial (inMIND) has demonstrated the efficacy of tafasitamab in combination with lenalidomide and rituximab for...